Angiotensin II receptor blockers induce autophagy in prostate cancer cells

Woo,Yunseo; Jung,Yu‑Jin

doi:10.3892/ol.2017.5872

Angiotensin II receptor blockers induce autophagy in prostate cancer cells

Authors:
- Yunseo Woo
- Yu‑Jin Jung
View Affiliations

Affiliations: Department of Biological Sciences and Bio‑Information Technology Medical Convergence Program, Kangwon National University, Chuncheon, Gangwon 200‑701, Republic of Korea
Published online on: March 17, 2017 https://doi.org/10.3892/ol.2017.5872
Pages: 3579-3585
Copyright: © Woo et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Angiotensin II receptor blockers (ARBs) are anti-hypertensive drugs that competitively inhibit the binding of angiotensin II to its receptor, resulting in blood vessel dilation and the reduction of blood pressure. These antagonists are also known as sartans, and are a group of pharmaceuticals that possess tetrazole or imidazole groups. In the present study, the anticancer and antimetastatic effects of the ARBs fimasartan, losartan, eprosartan and valsartan on the human prostate cancer PC‑3, DU‑145 and LNCap‑LN3 cell lines were investigated in vitro. The proliferation of the prostate cancer cells was inhibited following treatment with 100 µM ARB. In particular, treatment with fimasartan resulted in marked anti‑proliferative activity compared with the other ARBs. With respect to the molecular mechanism of the growth inhibition exhibited by the ARBs, 3‑methyladenin (3‑MA), an autophagy inhibitor, was revealed to increase the survival rate of PC‑3 cells when cell death inhibitors were pretreated with fimasartan. In addition, the ARBs induced autophagy with increased expression levels of autophagy protein (Atg) 5‑12, Atg 16‑like‑1, beclin‑1 and microtubule‑associated protein 1A/1B‑light chain 3 (LC3). Notably, the enhanced expression of LC3‑II (a 6.7‑fold increase at 72 h) was observed in PC3 cells treated with fimasartan. This was supported by the observation of the time‑dependent accumulation of LC3‑positive foci in PC‑3. In addition, a migration assay indicated that the ARBs induced anti‑metastatic effects in PC‑3 and DU‑145 cells. The aforementioned results suggest that ARBs may induce autophagy-associated cell death and anti‑metastatic activity in prostate cancer cells. Thus, ARBs may be a potential medication for patients with prostate cancer and hypertension.

View Figures

View References

1	Daniels N: Global aging and the allocation of health care across the life span. Am J Bioeth. 13:1–2. 2013. View Article : Google Scholar : PubMed/NCBI
2	Orom H, Penner LA, West BT, Downs TM, Rayford W and Underwood W: Personality predicts prostate cancer treatment decision-making difficulty and satisfaction. Psychooncology. 18:290–299. 2009. View Article : Google Scholar : PubMed/NCBI
3	Guxens M, Fitó M, Martínez-González MA, Salas-Salvadó J, Estruch R, Vinyoles E, Fiol M, Corella D, Arós F, Gómez-Gracia E, et al: Hypertensive status and lipoprotein oxidation in an elderly population at high cardiovascular risk. Am J Hypertens. 22:68–73. 2009. View Article : Google Scholar : PubMed/NCBI
4	Lin GM, Liu PY, Wu CF, Wang WB and Han CL: Carvedilol use and specific cancer risk in the population with hypertension. Int J Cardiol. 186:52–53. 2015. View Article : Google Scholar : PubMed/NCBI
5	Mouhayar E and Salahudeen A: Hypertension in cancer patients. Tex Heart Inst J. 38:263–265. 2011.PubMed/NCBI
6	Valcamonico F, Arcangeli G, Consoli F, Nonnis D, Grisanti S, Gatti E, Berruti A and Ferrari V: Idiopathic intracranial hypertension: A possible complication in the natural history of advanced prostate cancer. Int J Urol. 21:335–337. 2014. View Article : Google Scholar : PubMed/NCBI
7	Tahover E, Uziely B, Salah A, Temper M, Peretz T and Hubert A: Hypertension as a predictive biomarker in bevacizumab treatment for colorectal cancer patients. Med Oncol. 30:3272013. View Article : Google Scholar : PubMed/NCBI
8	Pant S, Martin LK, Geyer S, Wei L, Van Loon K, Sommovilla N, Zalupski M, Iyer R, Fogelman D, Ko AH and Bekaii-Saab T: Treatment-related hypertension as a pharmacodynamic biomarker for the efficacy of bevacizumab in advanced pancreas cancer: A pooled analysis of 4 prospective trials of gemcitabine-based therapy with bevacizumab. Am J Clin Oncol. 39:614–618. 2016. View Article : Google Scholar : PubMed/NCBI
9	Zhang J, Liu J, Chen J, Li X, Wu Y, Chen H, Wu W, Zhang K and Gu L: Angiotensin receptor blockers (ARBs) reduce the risk of lung cancer: A systematic review and meta-analysis. Int J Clin Exp Med. 8:12656–12660. 2015.PubMed/NCBI
10	Chae YK, Valsecchi ME, Kim J, Bianchi AL, Khemasuwan D, Desai A and Tester W: Reduced risk of breast cancer recurrence in patients using ACE inhibitors, ARBs, and/or statins. Cancer Invest. 29:585–593. 2011. View Article : Google Scholar : PubMed/NCBI
11	Mann SJ and Christos PJ: ACE inhibitors and ARBs: Do they reduce the risk of cancer? J Clin Hypertens (Greenwich). 16:6–7. 2014. View Article : Google Scholar : PubMed/NCBI
12	Sigmund CD: Structural biology: On stress and pressure. Nature. 468:46–47. 2010. View Article : Google Scholar : PubMed/NCBI
13	Asmar R: Targeting effective blood pressure control with angiotensin receptor blockers. Int J Clin Pract. 60:315–320. 2006. View Article : Google Scholar : PubMed/NCBI
14	van Zwieten PA: Angiotensin II receptor antagonists (AT1-blockers, ARBs, sartans): Similarities and differences. Neth Heart J. 14:381–387. 2006.PubMed/NCBI
15	Imai N, Hashimoto T, Kihara M, Yoshida S, Kawana I, Yazawa T, Kitamura H and Umemura S: Roles for host and tumor angiotensin II type 1 receptor in tumor growth and tumor-associated angiogenesis. Lab Invest. 87:189–198. 2007. View Article : Google Scholar : PubMed/NCBI
16	Rodrigues-Ferreira S, Abdelkarim M, Dillenburg-Pilla P, Luissint AC, di-Tommaso A, Deshayes F, Pontes CL, Molina A, Cagnard N, Letourneur F, et al: Angiotensin II facilitates breast cancer cell migration and metastasis. PLoS One. 7:e356672012. View Article : Google Scholar : PubMed/NCBI
17	Kosugi M, Miyajima A, Kikuchi E, Horiguchi Y and Murai M: Angiotensin II type 1 receptor antagonist candesartan as an angiogenic inhibitor in a xenograft model of bladder cancer. Clin Cancer Res. 12:2888–2893. 2006. View Article : Google Scholar : PubMed/NCBI
18	Rodrigues-Ferreira S, Morel M, Reis RI, Cormier F, Baud V, Costa-Neto CM and Nahmias C: A novel cellular model to study angiotensin II AT2 receptor function in breast cancer cells. Int J Pept. 2012:7450272012. View Article : Google Scholar : PubMed/NCBI
19	Carl-McGrath S, Ebert MP, Lendeckel U and Röcken C: Expression of the local angiotensin II system in gastric cancer may facilitate lymphatic invasion and nodal spread. Cancer Biol Ther. 6:1218–1226. 2007. View Article : Google Scholar : PubMed/NCBI
20	Matsuyama M, Funao K, Kuratsukuri K, Tanaka T, Kawahito Y, Sano H, Chargui J, Touraine JL, Yoshimura N and Yoshimura R: Telmisartan inhibits human urological cancer cell growth through early apoptosis. Exp Ther Med. 1:301–306. 2010.PubMed/NCBI
21	Uemura H, Ishiguro H, Nakaigawa N, Nagashima Y, Miyoshi Y, Fujinami K, Sakaguchi A and Kubota Y: Angiotensin II receptor blocker shows antiproliferative activity in prostate cancer cells: A possibility of tyrosine kinase inhibitor of growth factor. Mol Cancer Ther. 2:1139–1147. 2003.PubMed/NCBI
22	Uemura H, Hoshino K and Kubota Y: Role of renin-angiotensin system and antitumor effect of ARB in prostate cancer. Nihon Rinsho. 69:(Suppl 5). S155–S159. 2011.(In Japanese).
23	Uemura H and Kubota Y: Application of angiotensin II receptor blocker in prostate cancer. Nihon Rinsho. 67:807–811. 2009.(In Japanese). PubMed/NCBI
24	Funao K, Matsuyama M, Kawahito Y, Sano H, Chargui J, Touraine JL, Nakatani T and Yoshimura R: Telmisartan is a potent target for prevention and treatment in human prostate cancer. Oncol Rep. 20:295–300. 2008.PubMed/NCBI
25	Burikhanov R, Zhao Y, Goswami A, Qiu S, Schwarze SR and Rangnekar VM: The tumor suppressor Par-4 activates an extrinsic pathway for apoptosis. Cell. 138:377–388. 2009. View Article : Google Scholar : PubMed/NCBI
26	Okada H and Mak TW: Pathways of apoptotic and non-apoptotic death in tumour cells. Nat Rev Cancer. 4:592–603. 2004. View Article : Google Scholar : PubMed/NCBI
27	Kelly GL and Strasser A: The essential role of evasion from cell death in cancer. Adv Cancer Res. 111:39–96. 2011. View Article : Google Scholar : PubMed/NCBI
28	Kondo Y, Kanzawa T, Sawaya R and Kondo S: The role of autophagy in cancer development and response to therapy. Nat Rev Cancer. 5:726–734. 2005. View Article : Google Scholar : PubMed/NCBI
29	Mathew R, Karantza-Wadsworth V and White E: Role of autophagy in cancer. Nat Rev Cancer. 7:961–967. 2007. View Article : Google Scholar : PubMed/NCBI
30	Kang SJ, Tak JH, Cho JH, Lee HJ and Jung YJ: Stimulation of the endosomal TLR pathway enhances autophagy-induced cell death in radiotherapy of breast cancer. Genes & Genomics. 32:599–606. 2010. View Article : Google Scholar
31	Bose SK, Gibson W, Giri S, Nath N and Donald CD: Angiotensin II up-regulates PAX2 oncogene expression and activity in prostate cancer via the angiotensin II type I receptor. Prostate. 69:1334–1342. 2009. View Article : Google Scholar : PubMed/NCBI
32	Schweichel JU and Merker HJ: The morphology of various types of cell death in prenatal tissues. Teratology. 7:253–266. 1973. View Article : Google Scholar : PubMed/NCBI
33	Kroemer G and Levine B: Autophagic cell death: The story of a misnomer. Nat Rev Mol Cell Biol. 9:1004–1010. 2008. View Article : Google Scholar : PubMed/NCBI
34	Yosypiv IV, Schroeder M and El-Dahr SS: Angiotensin II type 1 receptor-EGF receptor cross-talk regulates ureteric bud branching morphogenesis. J Am Soc Nephrol. 17:1005–1014. 2006. View Article : Google Scholar : PubMed/NCBI
35	Yang WL, Perillo W, Liou D, Marambaud P and Wang P: AMPK inhibitor compound C suppresses cell proliferation by induction of apoptosis and autophagy in human colorectal cancer cells. J Surg Oncol. 106:680–688. 2012. View Article : Google Scholar : PubMed/NCBI
36	Galavotti S, Bartesaghi S, Faccenda D, Shaked-Rabi M, Sanzone S, McEvoy A, Dinsdale D, Condorelli F, Brandner S, Campanella M, et al: The autophagy-associated factors DRAM1 and p62 regulate cell migration and invasion in glioblastoma stem cells. Oncogene. 32:699–712. 2013. View Article : Google Scholar : PubMed/NCBI
37	Michaud M, Martins I, Sukkurwala AQ, Adjemian S, Ma Y, Pellegatti P, Shen S, Kepp O, Scoazec M, Mignot G, et al: Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science. 334:1573–1577. 2011. View Article : Google Scholar : PubMed/NCBI
38	Konstam MA, Neaton JD, Dickstein K, Drexler H, Komajda M, Martinez FA, Riegger GA, Malbecq W, Smith RD, Guptha S, et al: Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): A randomised, double-blind trial. Lancet. 374:1840–1848. 2009. View Article : Google Scholar : PubMed/NCBI
39	Abe M, Okada K, Maruyama T, Matsumoto S and Matsumoto K: Blood pressure-lowering and antiproteinuric effect of switching from high-dose angiotensin receptor blockers to normal-dose telmisartan and low-dose hydrochlorothiazide in hypertensive patients with chronic kidney disease. Int J Clin Pharmacol Ther. 48:206–213. 2010. View Article : Google Scholar : PubMed/NCBI
40	Colegio OR, Chu NQ, Szabo AL, Chu T, Rhebergen AM, Jairam V, Cyrus N, Brokowski CE, Eisenbarth SC, Phillips GM, et al: Functional polarization of tumour-associated macrophages by tumour-derived lactic acid. Nature. 513:559–563. 2014. View Article : Google Scholar : PubMed/NCBI
41	Yang M, Zheng J, Miao Y, Wang Y, Cui W, Guo J, Qiu S, Han Y, Jia L, Li H, et al: Serum-glucocorticoid regulated kinase 1 regulates alternatively activated macrophage polarization contributing to angiotensin II-induced inflammation and cardiac fibrosis. Arterioscler Thromb Vasc Biol. 32:1675–1686. 2012. View Article : Google Scholar : PubMed/NCBI